Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2

Targeted inhibition of Bruton’s Tyrosine Kinase (BTK) with ibrutinib and other agents has become important treatment options in chronic lymphocytic leukemia, Waldenström’s Macroglobulinemia, Mantle cell lymphoma, and non-GCB DLBCL. Clinical trials combining small molecule inhibitors with monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbarino, Verena, Henschke, Sinika, Blakemore, Stuart James, Izquierdo, Elena, Michalik, Michael, Nickel, Nadine, Möllenkotte, Indra, Vorholt, Daniela, Müller, Linda, Brinker, Reinhild, Fedorchenko, Oleg, Mikhael, Nelly, Seeger-Nukpezah, Tamina, Hallek, Michael, Pallasch, Christian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465917/
https://www.ncbi.nlm.nih.gov/pubmed/32824276
http://dx.doi.org/10.3390/cancers12082303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465917/
https://www.ncbi.nlm.nih.gov/pubmed/32824276
http://dx.doi.org/10.3390/cancers12082303

Ejemplares similares